High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 rituximab.
Becker
W
W
Department of Nuclear Medicine, University of Göttingen, Germany. wbecker@med-uni-goettingen.de
Behr
T
T
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000532:radiotherapy* / Q000628:therapy; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012074:Remission Induction; D000069283:Rituximab; D016879:Salvage Therapy; D014018:Tissue Distribution; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D000069283:Rituximab